Pfizer India and Cipla have entered into an exclusive agreement where Cipla will market and distribute four of Pfizer’s established brands in India. The brands include Corex Dx, Corex LS, Dolonex, and Neksium. Pfizer will continue to manufacture and supply these medicines to Cipla. This partnership aims to enhance the availability of these brands across India by leveraging Cipla’s distribution network.
Strategic Partnership with Cipla
Pfizer India has announced a strategic partnership with Cipla, granting Cipla exclusive rights to market and distribute key Pfizer brands within India. This agreement, effective December 19, 2025, leverages Cipla’s extensive distribution network to broaden the reach of essential medicines.
Brands Included in the Agreement
The exclusive marketing and distribution rights cover four key Pfizer brands:
- Corex Dx
- Corex LS
- Dolonex
- Neksium
Cipla will now be responsible for marketing, distributing, and selling these products across India. Pfizer will continue to handle the manufacturing and supply of these medicines to Cipla.
Rationale and Expected Benefits
This partnership allows Pfizer to extend the reach of its established brands to a wider patient base in India through Cipla’s extensive network. Cipla benefits by adding these well-known products to its portfolio, strengthening its presence in key therapy areas. Both companies expect this collaboration to improve healthcare access and outcomes for patients across India.
Comments from Leadership
Meenakshi Nevatia, Country President, Pfizer India, stated that the partnership will meet the needs of millions of patients across India effectively.
Achin Gupta, Global Chief Operating Officer, Cipla Ltd., emphasized that the partnership aligns with Cipla’s focus on building a formidable presence across key therapy areas and enhancing access to high quality treatments.
Source: BSE
